
    
      Patients who are scheduled to undergo high dose chemotherapy for multiple myeloma will
      receive in addition in a double blinded manner 60 ml of agaricus extract or placebo once
      daily from the start of stem cell mobilizing therapy until one week after the end of aplasia
      after high dose melphalan.

      Primary endpoints will be cytokine levels of degree of activation of tumor supressor genes
      before and after start of the investigational product.

      Secondary endpoints will be treatment response and quality of life.
    
  